Ebselen, an anti-inflammatory antioxidant

A great stroke association would finish off clinical testing of this to see if this would be useful for survivors. No one else is going to do it.
From this article;

The limits of lithium, and the hunt for a better alternative

 Ebselen, an anti-inflammatory antioxidant, was originally developed by Daiichi Sankyo, in Japan, to treat patients who had suffered a stroke. But the compound was never marketed and has since come off patent. It’s also part of the National Institutes of Health Clinical Collection—several hundred small molecules that have, to some extent, gone through the gamut of human clinical trials and have been found to be safe, but never reached final FDA approval.